Reset filter
Mots-clés
Haemophilus influenzae tyyppi b ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

169 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Concomitant Vaccination Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Concomitant Vaccination

- 17/07/2017 - 1 Formulaire, 1 Groupe Item, 4 Eléments de données, 1 Langue
Groupe Item: Concomitant Vaccination
Study part: Concomitant Vaccination. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Check for Study Continuation Visit 2 Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Check for Study Continuation Visit 2

- 16/07/2017 - 1 Formulaire, 1 Groupe Item, 9 Eléments de données, 1 Langue
Groupe Item: Check for Study Continuation
Study part: Check for Study Continuation Visit 2. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Vacccine Administration Booster Dose Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Vacccine Administration Booster Dose

- 16/07/2017 - 1 Formulaire, 3 Groupes Item, 21 Eléments de données, 1 Langue
Groupes Item: VACCINE ADMINISTRATION, Vaccine Administration Group Control, Vaccine administration cancelled
Study part: Vacccine Administration Booster Dose. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Adverse Events- Post- Vaccination Observation Booster Dose Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Adverse Events- Post- Vaccination Observation Booster Dose

- 16/07/2017 - 1 Formulaire, 1 Groupe Item, 2 Eléments de données, 1 Langue
Groupe Item: Adverse Events
Study part: Adverse Events- Post- Vaccination Observation Booster Dose. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Laboratory Tests Visit 2 Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Laboratory Tests Visit 2

- 16/07/2017 - 1 Formulaire, 1 Groupe Item, 4 Eléments de données, 1 Langue
Groupe Item: blood sample
Study part: Laboratory Tests Visit 2. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Pre- Vaccination Assessment Visit 1 Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Pre- Vaccination Assessment Visit 1

- 16/07/2017 - 1 Formulaire, 1 Groupe Item, 3 Eléments de données, 1 Langue
Groupe Item: Assessment Vaccination
Study part: Pre- Vaccination Assessment Visit 1 . A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

General Medical History/ Physical Examination Visit 1 Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - General Medical History/ Physical Examination Visit 1

- 16/07/2017 - 1 Formulaire, 1 Groupe Item, 27 Eléments de données, 1 Langue
Groupe Item: Physical Examination
Study part: General Medical History/ Physical Examination Visit 1. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Laboratory Tests Visit 1 Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Laboratory Tests Visit 1

- 16/07/2017 - 1 Formulaire, 1 Groupe Item, 3 Eléments de données, 1 Langue
Groupe Item: blood sample
Study part: Laboratory Tests Visit 1. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Eligibility Question Visit 1 Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Eligibility Question Visit 1

- 16/07/2017 - 1 Formulaire, 3 Groupes Item, 21 Eléments de données, 1 Langue
Groupes Item: Eligibility Question, Inclusion Criteria, Exclusion Criteria
Study part: Eligibility Question Visit 1. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Demographics Visit 1 Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Demographics Visit 1

- 16/07/2017 - 1 Formulaire, 1 Groupe Item, 4 Eléments de données, 1 Langue
Groupe Item: Demographics
Study part: Demographics Visit 1. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Eligibility Haemophilus Influenzae Type B NCT00441012

- 11/04/2017 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED); ODM derived from: https://clinicaltrials.gov/show/NCT00441012

Eligibility Hib Disease NCT00317187

- 23/09/2016 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.; ODM derived from: https://clinicaltrials.gov/show/NCT00317187

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial